Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Amubarvimab (BRII-196), a human IgG1 monoclonal antibody (mAb), targets non-competing epitopes on the receptor binding domain (RBD) of the spike protein, exhibiting a dissociation constant (K D) of 5.88 nM. It has demonstrated efficacy in neutralizing SARS-CoV-2 variants [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry |
Description | Amubarvimab (BRII-196), a human IgG1 monoclonal antibody (mAb), targets non-competing epitopes on the receptor binding domain (RBD) of the spike protein, exhibiting a dissociation constant (K D) of 5.88 nM. It has demonstrated efficacy in neutralizing SARS-CoV-2 variants [1] [2]. |
Molecular Weight | N/A |
CAS No. | 2509447-07-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Amubarvimab 2509447-07-6 inhibitor inhibit